GlassScriptPhysician profile
Heidi M Webb
NPI 1316296551
$9,824.94
in general payments reported to CMS, 2019-2025
47 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,238 · 2022: $2,060 · 2023: $2,333 · 2024: $1,895 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,486 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,486.18 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,074.34 | 2021-2025 | Wegovy, Ozempic, Saxenda |
| Bayer Healthcare Pharmaceuticals INC. | $958.12 | 2021-2025 | |
| Dexcom, INC. | $797.94 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $785.14 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Sanofi-Aventis U.S. LLC | $768.83 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $717.89 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $540.67 | 2021-2025 | Evenity, Prolia, Prolia |
| Abbott Laboratories | $524.71 | 2021-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $406.87 | 2021-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $323.59 | 2021-2024 | Farxiga |
| Abbvie INC. | $298.80 | 2021-2025 | |
| Becton, Dickinson and Company | $245.52 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $196.82 | 2021-2024 | Unithroid |
| Xeris Pharmaceuticals, INC. | $189.92 | 2021-2025 | Recorlev |
| Insulet Corporation | $173.00 | 2021-2025 | Omnipod |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $145.05 | 2022-2023 | Afrezza |
| Alexion Pharmaceuticals, INC. | $144.55 | 2021-2025 | Strensiq |
| Medtronic, INC. | $109.39 | 2022-2025 | Minimed 780g |
| Neurocrine Biosciences, INC. | $108.18 | 2024-2025 | |
| Esperion Therapeutics, INC. | $90.59 | 2021 | |
| Antares Pharma, INC. | $80.24 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Kowa Pharmaceuticals America, INC. | $79.32 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $76.25 | 2021-2023 | Verquvo, Steglatro, Januvia |
| E.R. Squibb & Sons, L.L.C. | $71.86 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $69.55 | 2022 | |
| Ascendis Pharma Endocrinology INC | $66.64 | 2023-2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $66.17 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amphastar Pharmaceuticals, INC. | $64.86 | 2024-2025 | |
| Embecta Corp. | $60.42 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Zealand Pharma US, INC. | $59.70 | 2022 | |
| Sequel Med Tech, LLC | $55.34 | 2025 | Twiist |
| Pfizer INC. | $44.29 | 2024 | |
| Arbor Pharmaceuticals, INC. | $39.47 | 2021 | |
| Glaxosmithkline, LLC. | $39.04 | 2023-2024 | Trelegy Ellipta |
| Radius Health, INC. | $38.73 | 2023-2025 | Tymlos |
| Amarin Pharma, INC. | $36.24 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $34.77 | 2021 | |
| Cequr Corporation | $34.20 | 2022-2023 | Cequr Simplicity |
| Kyowa Kirin, INC. | $33.48 | 2024 | Crysvita |
| Novartis Pharmaceuticals Corporation | $31.60 | 2024 | |
| Averitas Pharma INC. | $30.26 | 2025 | Qutenza |
| Acerus Pharmaceuticals Corporation | $29.24 | 2021 | |
| Endo Pharmaceuticals INC. | $21.66 | 2021 | |
| Beta Bionics, INC. | $17.35 | 2023 | Ilet Bionic Pancreas |
| Nevro Corp. | $16.71 | 2021 | |
| Madrigal Pharmaceuticals | $14.61 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.